Precigen
Biopharmaceutical company developing gene and cell therapies across immuno-oncology, autoimmune and infectious disease. Operates platforms for adenoviral vector immunotherapies and non-viral multigenic CAR-T, advances programs through preclinical and clinical development, and has a marketed adenoviral vector immunotherapy for recurrent respiratory papillomatosis.
Industries
Nr. of Employees
large (251-1000)
Patents
Products
PAPZIMEOS (zopapogene imadenovec‑drba)
Non‑replicating adenoviral vector‑based immunotherapy indicated for treatment of adults with recurrent respiratory papillomatosis; provided as a frozen single‑dose suspension for subcutaneous injection with a specified dosing schedule.
PAPZIMEOS (zopapogene imadenovec‑drba)
Non‑replicating adenoviral vector‑based immunotherapy indicated for treatment of adults with recurrent respiratory papillomatosis; provided as a frozen single‑dose suspension for subcutaneous injection with a specified dosing schedule.
Services
Policy and contact pathway for physicians requesting pre‑approval access to investigational therapies.
Policy and contact pathway for physicians requesting pre‑approval access to investigational therapies.
Expertise Areas
- Gene and viral vector therapy development
- Autologous CAR‑T engineering and rapid manufacturing
- Non‑viral genome engineering and integration systems
- Translational immunology and vaccine research
Key Technologies
- Adenoviral vector systems for in vivo immunotherapy
- Non‑viral transposon/transposase delivery
- Site‑specific recombinase integration
- Electroporation systems for cell modification
News & Updates
Publication reporting results from a pivotal Phase 1/2 clinical trial of an adenoviral vector therapy in recurrent respiratory papillomatosis.
Study linking tumor microenvironment state to response to HPV therapeutic vaccination in patients with respiratory papillomatosis.
U.S. regulatory approval and full prescribing information issued for an adenoviral vector‑based immunotherapy for adults with recurrent respiratory papillomatosis (initial U.S. approval: 2025).
Publication reporting results from a pivotal Phase 1/2 clinical trial of an adenoviral vector therapy in recurrent respiratory papillomatosis.
Study linking tumor microenvironment state to response to HPV therapeutic vaccination in patients with respiratory papillomatosis.
U.S. regulatory approval and full prescribing information issued for an adenoviral vector‑based immunotherapy for adults with recurrent respiratory papillomatosis (initial U.S. approval: 2025).